Parkinson's Disease Therapeutics

Parkinson's Disease Therapeutics: Emphasis on Nanotechnological Advances presents the latest information on the second most common neurodegenerative disorder in the elderly. Despite remarkable progress in various PD therapeutics, such as microRNAs and brain drug delivery systems, a few limitations impede their success. This book sheds light on the pros and cons of recently developed novel therapeutics. Very few books have highlighted the protective efficacy of natural products, antioxidants, and biomaterial design for other diseases. - Emphasizes novel therapeutics for Parkinson's disease, including nanotechnology, natural products and antioxidants - Discusses the pros and cons of recently developed therapy options for Parkinson's - Focuses on the efficacy of nanotechnology in overcoming the blood-brain barrier and biomaterial design

Magisetty Obulesu is a research associate at the Regional Agricultural Research Station, Acharya N.G. Ranga Agricultural University, Tirupati, India. He has 20 years of research and teaching experience. He is also an editorial board of nanotechnology journals including SciFed Nanotech Research Letters, SciFed Drug Delivery Research, Current Updates in Nanotechnology and Journal of Nanotechnology and Materials Science. His research areas include food science, pathology of neurodegenerative diseases such as Alzheimer's disease, designing polymer-based biomaterials such as hydrogels, and development of metal chelators to overcome metal induced toxicity. He has researched Alzheimer's disease and developed an aluminium-induced neurotoxicity rabbit model. Mr. Obulesu's present research focuses on development of redox-active injectable hydrogels of polyion complex. He has written three books and edited two more; he is also the first and corresponding author for majority of his articles.